Revolutionizing Performance Measurement: Industry-First Methodology for Testing 5G Network Slices Enabled by Ookla and Ericsson

 SEATTLE - 

Specialized Speedtest app enabling real-time validation of differentiated 5G connectivity to be showcased at MWC Barcelona 2026

(BUSINESS WIRE)--Ookla®, a global leader in connectivity intelligence, and Ericsson, a world leader in communications technology, demonstrate an innovative solution allowing users to measure and validate 5G network slicing performance. This collaboration marks a major milestone in the 5G-Advanced era, providing a way to validate the Quality of Experience (QoE) essential for the next generation of mobile applications and use cases.

Historically, measuring the performance of an individual network slice from a consumer or enterprise device has been a significant technical challenge. Traditional speed tests measure the default internet connection.

Through this collaboration, Ookla and Ericsson developed a methodology that enables the Speedtest app to identify and test specific network slices. This breakthrough demonstrates how Service Level Agreements (SLAs) for differentiated services can finally be verified in real-time by both consumers using the Speedtest app and service providers.

Crucially, this puts the power of verification directly into the hands of the consumer, allowing them to use the unique Speedtest app to independently validate that the performance they’ve purchased is being delivered as promised.

"Network slicing is no longer a future concept; it is a commercial reality. However, you cannot manage what you cannot measure," said Tibor Rathonyi, Senior Advisor at Ookla. "Our work with Ericsson is a pivotal first step in providing the transparency needed to prove the value of these premium 5G services to both consumers and enterprises."

As 5G Standalone (SA) deployments scale globally, network slicing has emerged as the critical catalyst for 5G monetization. The technology allows operators to create multiple virtual networks (slices) over a single physical infrastructure, each tailored to specific requirements:

Ultra-low latency for gaming,

High-bandwidth for 8K video streaming,

Mission-critical reliability for industrial IoT and emergency services.

MWC 2026 Live Demonstration

The results of this collaboration between Ookla and Ericsson will debut during Mobile World Congress (MWC) Barcelona 2026. Attendees can visit the Ericsson pavilion, in Hall 2, to experience a live demonstration of a specialized test version of the Speedtest® app, featuring:

Side-by-Side Comparison: Visualizing the performance gap between a standard 5G connection and a service-specific slice within Ericsson’s live 5G network at the venue.

SLA Verification: Real-time reporting on Key Performance Indicators (KPIs) within a dedicated slice to prove guaranteed quality of service.

About Ookla®

Ookla, a global leader in connectivity intelligence, brings together the trusted expertise of Speedtest®, Downdetector®, Ekahau®, and RootMetrics® to deliver unmatched network and connectivity insights. By combining multi-source data with industry-leading expertise, we transform network performance metrics into strategic, actionable insights.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223609962/en/

Permalink

https://www.aetoswire.com/en/news/54429389

Contacts

 

Raquel Sanz

Communications Manager

Ookla

press@ookla.com

 

Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies

 Angelini Pharma secures exclusive global license rights to future identified drug targets

Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties

Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience

 

(BUSINESS WIRE)--Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/

Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receive additional milestones payments of up to $120 million and additional royalties upon Angelini’s election of drug targets identified through the collaboration.

“The prospects of our collaboration with Quiver Bioscience are very promising,” said Rafal Kaminski, MD, PhD, Chief Scientific Officer at Angelini Pharma.” The aim is to generate novel scientific insights on a scale and richness that has been unprecedented in this area of research. By applying cutting-edge technologies and advanced data analytics approaches, including AI, this partnership will generate a unique data set to inform the development of novel therapies in the future.”

In its latest collaboration, Angelini Pharma will leverage Quiver’s technology platform to break new grounds in deeper understanding a broad set of Developmental and Epileptic Encephalopathies (DEEs). DEEs are a group of rare diseases affecting children worldwide, causing a spectrum of neurodevelopmental symptoms and severe treatment-resistant seizures linked to genetic mutations. They are often caused by gene mutations, but functional and molecular consequences of such mutations are not well understood in most cases. Despite introduction of recently approved treatments for some DEEs, there is still a pressing unmet need for more effective therapies. Quiver Bioscience's advanced platform uses human neuronal models coupled with single-cell transcriptomic resolution, optical electrophysiology, and AI to accelerate the discovery of precision therapies for these complex conditions. The ultimate goal of the partnership is to discover and develop differentiated therapeutics that can address multiple DEEs.

“We’re excited to embark on this collaboration with the excellent team at Angelini Pharma,” said Graham T. Dempsey, PhD, Co-founder and Chief Executive Officer at Quiver Bioscience. “Together we are pursuing a novel approach uniquely enabled by Quiver’s technology platform. By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers. We look forward to translating this science into new medicines for a disease area in urgent need of innovation.”

“This new partnership is another step forward to advance our strategic priorities, strengthen our global presence and potentially expand our pipeline of innovative medicines and promising candidates”, said Sergio Marullo di Condojanni, Chief Executive Officer at Angelini Pharma. “It follows a number of strategic acquisitions and collaboration agreements that we have entered over the course of the past two years and will further boost our leadership and portfolio in brain health”.

Destum Partners acted as transaction advisor to Quiver Bioscience.

About Quiver Bioscience

Quiver Bioscience is a technology-driven biotechnology company focused on accelerating discovery of empirically grounded, AI-driven therapeutics that deliver transformative value to patients with neurological disease. Quiver has built the first-of-its kind perturbation atlas of neuronal behavior using its proprietary Genomic Positioning System (GPS) platform, enabling precise target identification, functional validation, and safety assessment. Their empirical-in-a-loop approach integrates scalable human neuronal models, advanced single-cell optical electrophysiology and multi-omics techniques, with machine learning and surrogate models, to identify novel therapeutic targets and optimal candidate molecules. For information, including scientific publications describing the application of Quiver’s GPS platform to drug discovery, visit www.quiverbioscience.com.

About Angelini Pharma

Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. More information: https://www.angelinipharma.com.

About Angelini Industries

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates. To learn more visit https://www.angeliniindustries.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223465174/en/

Permalink

https://www.aetoswire.com/en/news/2302202653490-1

Contacts

Media Contact

For Angelini Pharma:

Chiara Antoniucci

chiara.antoniucci@angelinipharma.com

For Quiver Bioscience:

Noélle Germain

noelle.germain@quiverbioscience.com

IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.

  • Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally.

• Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre.

• The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public.

• With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2

• Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025.

• Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG.

• Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-qubit gates and readouts in their processors, and on track to deliver broad commercialization with the release of its next generation system, Halocene.

 

(BUSINESS WIRE)--IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading provider of quantum computers.

Headquartered in Finland, IQM is also considering a dual listing that would see the trading of IQM’s ordinary shares on the Helsinki stock exchange, which would be expected to take place following the completion of this transaction.

IQM is a quantum computing company that builds full stack, open-architecture systems that can be deployed on-premise or accessed via the cloud. IQM operates a vertically integrated business model, boasting a unique combination of proprietary infrastructure from their own chip design tool and software developer platform, to a quantum chip fab, assembly line and data centre, allowing the company to accelerate its innovation cycles, deliver best-in-class quantum computing to its customers and enabling the quantum ecosystem to grow.

Transaction Highlights:

Following completion of the transaction, IQM’s cash on its balance sheet is expected to be in excess of USD 450 million cash at closing4 (including IQM’s existing cash), providing runway for continued broad commercial advantage:

• Approximately USD 175 million of cash held in RAAQ’s trust account (based on the current amount in the trust account and assuming no redemptions);

• Approximately USD 134 million in proceeds from a PIPE financing at USD 10.00 per share from leading new and existing and institutional investors, to close concurrently with the business combination, subject to the satisfaction of certain customary closing conditions;

• Expected USD 24 million in proceeds from the cash exercise of outstanding IQM warrants prior to the closing;

• Existing cash on IQM’s balance sheet of USD 172 million (unaudited as of year-end 2025); and

•  The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion.

Jan Goetz, Co-Founder and Chief Executive Officer, IQM, said: “We built IQM from the beginning for one purpose — to put working quantum computers in the hands of the people who will use them to solve real problems. Not someday. Now. Quantum computing is a science project no more. It is an industry where customers own, operate, and build on advanced quantum computers. That’s what IQM makes possible.”

Peter Ort, Chief Executive Officer and Co-Chairman, Real Asset Acquisition Corp, said: “IQM has built and delivered more on-premises quantum systems than any other competitor5 — to some of the most demanding research institutions on earth. This transaction will accelerate the growth of a company that has already earned its position in the field, with real customers, running real quantum systems, today.”

Sierk Poetting, Chairman of IQM’s Board of Directors, said: “Going public is not a change of direction but is rather an acceleration. The board stands fully behind IQM’s mission and goals to make quantum infrastructure as foundational and accessible as classical computing.”

The existing IQM shareholders will not sell any shares or receive any cash consideration as part of the transaction and all material IQM shareholders have committed to a customary lock-up agreement at close of this transaction.

The board of directors of both IQM and RAAQ have each unanimously approved the proposed business combination. The closing of the proposed business combination is subject to, among other things, the approval by shareholders of RAAQ and IQM of the business combination agreement and the satisfaction of other customary closing conditions.

Additional information about the proposed business combination, including a copy of the business combination agreement, will be provided in a Current Report on Form 8-K to be filed by RAAQ with the Securities and Exchange Commission (the “SEC”).

The securities being sold in the PIPE financing have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws and accordingly may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Conference Call Information

Management of IQM and RAAQ will host an investor conference call to discuss the proposed transaction and review an investor presentation, with exact details to be updated and confirmed with a follow-up announcement. Interested investors will be able to access a recording of the conference call by visiting https://meetiqm.com/investors/. A transcript of the call will also be filed by RAAQ with the SEC.

Advisors

J.P. Morgan SE is serving as financial advisor and capital market advisor to IQM. J.P. Morgan Securities LLC and TD Cowen are serving as PIPE placement agents to IQM. Rothschild & Co. is serving as financial advisor and capital markets advisor to IQM’s and its Board of Directors. TD Cowen is serving as financial advisor and capital markets advisor to RAAQ. Cohen & Company Capital Markets is serving as a capital markets advisor to RAAQ. Cooley LLP and Borenius Attorneys Ltd are serving as legal advisors to IQM, and Perkins Coie LLP, Krogerus Attorneys Ltd and Conyers Dill & Pearman LLP are serving as legal advisors to RAAQ. DLA Piper LLP (US) is serving as legal advisor to J.P. Morgan Securities LLC and TD Cowen. The Blueshirt Group is serving as investor relations advisor to IQM.

About IQM Quantum Computers

IQM Finland Oy (“IQM”, “IQM Quantum Computers”, “Company”) is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its systems. IQM customers include leading high-performance computing centres, research laboratories, universities, and enterprises that require full access to quantum hardware and software. IQM has over 300 employees, with headquarters in Finland and a global presence including France, Germany, Italy, Japan, Poland, Saudi Arabia, Spain, Singapore, South Korea, Taiwan, UK and the United States.

About Real Asset Acquisition Corp.

Based in Princeton, NJ, Real Asset Acquisition Corp. is a Nasdaq-listed (Nasdaq: RAAQ) special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The RAAQ team includes seasoned quantum computing experts with deep technical and industry experience.

1 Represent publicly announced on-premises deliveries from each of IBM, D-Wave, Pasqal, Rigetti, IonQ, OQC, Quandela, Anyon Systems, QuEra, Atom Computing and Quantinuum

2 Inclusive of cash commitments in excess of $130M from the PIPE, in addition to approximately $24M from expected exercises of warrants prior to transaction close, in addition to cash proceeds of the RAAQ trust (assuming nil redemptions) and IQM existing cash as of 12/31/25, less expected transaction expenses of $25M

3 Exchange rate of EUR/USD of 1.174 as of December 31, 2025

4 Inclusive of cash commitments in excess of $130M from the PIPE, in addition to approximately $24M from expected exercises of warrants prior to transaction close, in addition to cash proceeds of the RAAQ trust (assuming nil redemptions) and IQM existing cash as of 12/31/25, less expected transaction expenses of $25M

5 Represent publicly announced on-premises deliveries from each of IBM, D-Wave, Pasqal, Rigetti, IonQ, OQC, Quandela, Anyon Systems, QuEra, Atom Computing and Quantinuum

Additional Information About the Proposed Transaction and Where to Find It

In connection with the proposed business combination, IQM intends to file with the SEC a registration statement on Form F-4 (the “Registration Statement”), which will include a preliminary proxy statement of RAAQ and a preliminary prospectus of IQM, and after the Registration Statement is declared effective by the SEC, RAAQ will mail the definitive proxy statement/prospectus relating to the proposed business combination to its shareholders as of a record date to be established for voting at the extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”). The Registration Statement, including the proxy statement/prospectus contained therein, will contain important information about the proposed business combination and the other matters to be voted upon at the Extraordinary General Meeting. This communication does not contain all the information that should be considered concerning the proposed business combination and is not intended to provide the basis for any investment decision or any other decision in respect of such matters. RAAQ and IQM may also file other documents with the SEC regarding the proposed business combination. RAAQ’s shareholders and other interested persons are advised to read, when available, the Registration Statement, including the preliminary proxy statement/prospectus contained therein, the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about RAAQ, IQM and the proposed business combination. Shareholders may obtain copies of the Registration Statement, including the preliminary or definitive proxy statement/prospectus contained therein, and the other documents filed or that will be filed by RAAQ and IQM with the SEC, once available, without charge, at the SEC’s website located at www.sec.gov.

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the U.S. federal securities laws and “forward-looking information” within the meaning of applicable non-U.S. securities laws (collectively, “forward-looking statements”). Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based upon current estimates and assumptions that, while considered reasonable by IQM and its management, and RAAQ and its management, as the case may be, are inherently uncertain. These statements include: projections of market opportunity and market share; estimates of customer adoption rates and usage patterns; projections regarding the Company’s ability to commercialize new products and technologies; projections of development and commercialization costs and timelines; expectations regarding the Company’s ability to execute its business model and the expected financial benefits of such model; expectations regarding the Company’s ability to attract, retain and expand its customer base; the Company’s deployment of proceeds from capital raising transactions; the Company’s expectations concerning relationships with strategic partners, suppliers, governments, state-funded entities, regulatory bodies and other third parties; the Company’s ability to maintain, protect and enhance its intellectual property; future ventures or investments in companies, products, services or technologies; development of favorable regulations affecting the Company’s markets; the successful consummation and potential benefits of the proposed business combination and expectations related to its terms and timing; the stock exchanges on which the securities of the combined company are expected to trade; proceeds from the business combination and related PIPE; funds received by the combined company from RAAQ’s trust account and redemptions by RAAQ’s public shareholders; the Company’s ability to commercialize its hardware and software; the expectation that the Company is building the sovereign infrastructure that allows quantum ecosystems to grow; and the potential for the Company to increase in value.

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of the Company and RAAQ.

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause the actual results of the combined company following the proposed transaction, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that the Company is pursuing an emerging technology, which faces significant technical challenges and may not achieve commercialization or market acceptance; the Company’s historical net losses and limited operating history; the Company’s expectations regarding future financial performance, capital requirements and unit economics; the Company’s use and reporting of business and operational metrics; the Company’s competitive landscape; the Company’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; the Company’s concentration of revenue in contracts with government or state-funded entities; the Company’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; the Company’s reliance on strategic partners and other third parties; the Company’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; the combined company’s ability to maintain internal control over financial reporting and operate a public company; the possibility that required shareholder and regulatory approvals for the proposed transaction are delayed or are not obtained, which could adversely affect the combined company or the expected benefits of the proposed transaction; the risk that shareholders of RAAQ could elect to have their shares redeemed, leaving the combined company with insufficient cash to execute its business plans; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings or government investigations that may be commenced against the Company or RAAQ; failure to realize the anticipated benefits of the proposed transaction; the ability of IQM or the combined company to issue equity or equity-linked securities in connection with the proposed transaction or in the future; and other factors described in RAAQ’s and the Company’s filings with the SEC. These forward-looking statements are based on certain assumptions, including that none of the risks identified above materialize; that there are no unforeseen changes to economic and market conditions, and that no significant events occur outside the ordinary course of business. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by the Company, RAAQ or the combined company resulting from the proposed business combination with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of the Company’s and RAAQ’s management as of the date of this communication; subsequent events and developments may cause their assessments to change. While the Company and RAAQ may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so, unless required by applicable securities laws. Accordingly, undue reliance should not be placed upon these statements.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this communication, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. An investment in RAAQ is not an investment in any of RAAQ’s founders’ or sponsors past investments, companies, or affiliated funds. The historical results of those investments are not indicative of future performance of RAAQ, which may differ materially from the performance of RAAQ’s founders’ or sponsors past investments.

Participants in the Solicitation

RAAQ, the Company and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from RAAQ’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of RAAQ’s shareholders in connection with the proposed transaction will be set forth in the Registration Statement, including the proxy statement/prospectus contained therein, when it is filed with the SEC. You can find more information about RAAQ’s directors and executive officers in RAAQ’s final prospectus related to its initial public offering filed with the SEC on May 15, 2025 and in the subsequent Quarterly Reports on Form 10-Q filed by RAAQ with the SEC. Shareholders, potential investors, and other interested persons should read the Registration Statement, including the proxy statement/prospectus contained therein, carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources described above.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction, including any European Economic Area member state or the United Kingdom. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. Any potential dual listing of IQM’s ordinary shares on the Helsinki stock exchange referred to in this communication would be made by means of a prospectus as set out in the EU Prospectus Regulation. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223639678/en/

Permalink

https://www.aetoswire.com/en/news/2302202653490

Contacts

Media contact:

Michael Bruce

PR Manager

press@meetiqm.com

Investor contact:

Blair Robertson

VP, Strategy

ir@meetiqm.com

Arabian Ethicals Leads Global Discussion on Cell and Gene Therapy at WHX Dubai 2026

Arabian Ethicals, a Ghobash Group enterprise, lead an insightful global discussion on cell and gene therapy at World Health Expo (WHX) Dubai 2026, the largest international gathering of healthcare professionals. Serving as a global platform for knowledge exchange and the advancement of healthcare practice, WHX Dubai took place at Expo City Dubai from 9 to 12 February.

The panel was moderated by Ebru Yavuz, General Manager of Arabian Ethicals in the UAE, who guided the discussion on how advances in stem cell, cellular, and gene therapies are being implemented within real-world healthcare settings. Titled “Cell & Gene Therapy Waves: From Scientific Breakthroughs to Real-World Clinical Delivery,” the session examined readiness, infrastructure, and long-term considerations influencing the adoption of these therapies.

Throughout the discussion, Yavuz facilitated conversations around the operational and clinical realities faced by healthcare providers. Topics included the need for specialised facilities, multidisciplinary expertise, and clearly defined care pathways, alongside the importance of responsible scaling as advanced therapies move closer to routine clinical use.

The session featured Prof. Marcos De Lima, Director of Stem Cell Transplant and Cellular Therapy at Ohio State University Wexner Medical Center, and Rabi Hanna, Chairman of Pediatric Hematology & Oncology and BMT, and Founding Director of the Pediatric Blood & Marrow Transplant Program at Cleveland Clinic Children’s Hospital, USA. Both speakers shared insights drawn from established transplant and cellular therapy programmes, highlighting recent developments as well as ongoing challenges associated with translating complex therapies into everyday clinical practice.

A key focus of the panel was pediatric care, where cell and gene therapies introduce additional clinical, logistical, and ethical considerations. The discussion addressed the importance of long-term follow-up, patient selection, and institutional readiness, as well as the role of academic medical centres in setting standards and supporting sustainable growth in the field.

Commenting on the panel, Ebru Yavuz noted: “Innovation in cell and gene therapy is moving quickly, but the real challenge lies in how these advances are adopted within healthcare systems. Forums like WHX Dubai allow practitioners and industry leaders to share practical experience and discuss what is needed to deliver these therapies safely and effectively in clinical settings.”

The discussion aligns with the UAE’s broader healthcare ambitions, which prioritise quality, innovation, and integrated care as part of the country’s long-term national vision through 2031. Platforms such as WHX Dubai support these priorities by facilitating knowledge exchange and collaboration across specialised and emerging areas of healthcare.

Arabian Ethicals’ participation at WHX Dubai 2026 reflects its continued engagement in scientific dialogue and support for knowledge exchange across specialised therapeutic areas, contributing to the ongoing development of healthcare practice in the region.

About Arabian Ethicals

Established in 1977, Arabian Ethicals – a Ghobash Group Enterprise – is a leading UAE-based healthcare distributor with a strong focus on pharmaceuticals, consumer health, and animal care. The company enables global partners to navigate the UAE market through regulatory expertise, strong public-private relationships, and deep regional insight. With a portfolio spanning high-impact therapeutic areas such as oncology and diabetes, Arabian Ethicals is committed to improving patient access and advancing healthcare outcomes across the region.

 

For more information, visit arabianethicals.ae or write to info@arabianethicals.ae. You can also follow Arabian Ethicals on LinkedIn.

Permalink
https://aetoswire.com/en/news/ae23022026e

Contacts

Tony Hamad

Group Marketing Director

+971 4 5961800

The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience

 NEW YORK - Monday, 23. February 2026

Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes

 

(BUSINESS WIRE)--Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations.

“From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-famous Observatory, a private party room with a Ghirardelli sundae chef, Empire State Building party favors, and so much more.”

The ESB Birthday Party Package includes a guided visit through the Observatory’s galleries and New York City’s best views on the 86th Floor deck, a private party room with a Ghirardelli Chocolate & Ice Cream Shop sundae chef, artisanal snacks and drinks, professional face painting and balloon twisting, and ESB-themed evites and party favors. For the ultimate experience, celebrants can include a visit to the premium 102nd Floor Observatory and can even add a visit from the Empire State Building’s beloved mascot, Emma Pire. The package includes a party for 12 children and three adults, which can be expanded to accommodate up to 25 guests. ESB Birthday Party Packages must be booked at least 28 days in advance at esbnyc.com and are available for celebrations on Saturdays and Sundays from 10 a.m. to 3 p.m.

The Empire State Building’s world-famous Observatory Experience recently underwent a $165 million upgrade that features an interactive museum with nine galleries, brand-new host uniforms, and a reimagined 102nd Floor Observatory.

Hi-res imagery for the Empire State Building Observatory and its new Birthday Package can be downloaded here. More information about the Empire State Building and the ESB Birthday Party Package can be found online.

About the Empire State Building

The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience created an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and is ranked the #1 Top Attraction in New York City for the fourth consecutive year in Tripadvisor’s 2025 Travelers’ Choice Awards: Best of the Best Things to Do, "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223161708/en/

Permalink

https://www.aetoswire.com/en/news/2302202653492

Contacts

MEDIA:

Empire State Realty Trust

Jamie Heitner

212-400-3339

jheitner@esrtreit.com

 

AOP Health on Rare Diseases: Information. Collaboration. Innovation.

 

VIENNA 

Why closing knowledge gaps matters for patients, healthcare and innovation.

(BUSINESS WIRE)--Between 27 and 36 million1 people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment2. Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases.

“Working in rare diseases since 1996 has shown us that innovation is never a solo effort,” emphasized Melissa Fellner, Vice President Global Therapeutic Areas at AOP Health. “It requires continuous investment in data, open collaboration and information that reaches patients in a form they can use.”

Consistent with this approach, AOP Health is conducting five clinical studies in the field of rare diseases. The company collaborates with researchers at numerous renowned international universities, as well as 58 patient organizations, most of which focus on rare diseases. These partnerships aim to leverage synergies and to strengthen the evidence base.

Collaboration is key

Prof. Dr. med. Haifa Kathrin Al-Ali, a professor of internal medicine at Halle (Saale) University Hospital and Director of the Krukenberg Cancer Center Halle, shares AOP Health’s perspectives. " Without informed patients, it is difficult to generate evidence that truly represents daily clinical reality," she said. "Close collaboration and an exchange on equal footing are therefore essential, especially in rare diseases.”

Thus, cooperation between physicians, patients and the pharmaceutical industry plays a crucial role in advancing research.

New EU regulations require informed patients

Furthermore, patient involvement is becoming increasingly central to European evaluation and decision-making processes. New frameworks, such as joint clinical assessments (JCAs), and structured evaluation approaches, such as PICO (which defines populations, comparators, and patient-relevant outcomes), explicitly rely on evidence that reflects real-world needs and experiences. Therefore, robust, patient-relevant data and informed patient perspectives are becoming increasingly critical.

However, meaningful patient participation in these processes requires access to appropriate knowledge and competencies. Eva Otter, Vice President of PHA Europe, a patient advocacy group representing people living with pulmonary hypertension globally emphasizes, "To meet European requirements and participate effectively in evaluation processes, we need access to reliable, evidence-based information presented in a language we can understand. Patient-friendly expert information is therefore not an add-on, but a prerequisite for informed participation and credible assessments."

Rare Disease Day 2026: Extending access to patient-centred information

To coincide with Rare Disease Day 2026, AOP Health is releasing a new episode of its German-language patient podcast to support patients in processing their diagnosis. This episode focuses on health literacy and addresses a central question: How can patients become well-informed and actively engaged in their care?

Links

Take a look at aop-health.com from 26.2.-2.3.2026 for a Rare Disease Day special and listen to the podcast „Ab jetzt ist alles anders? Leben nach und mit einer schwerwiegenden Diagnose“. (“Everything's Different Now? Life After and With a Serious Diagnosis") here.

About AOP Health

AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company’s actions. (aop-health.com)

1 https://health.ec.europa.eu/european-reference-networks/rare-diseases_en

2 https://www.eurordis.org/rare-disease-policy/european-policy/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223167500/en/

Permalink

https://www.aetoswire.com/en/news/54429786

Contacts

 

Further inquiry

DI Isolde Fally

Isolde.Fally@aop-health.com

https://www.aop-health.com

Axelspace Secures Japan Ministry of Defense Satellite Constellation Project

 As an optical imagery provider, Axelspace has entered into a contract for the acquisition of image data

(BUSINESS WIRE) -- Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that, for the purpose of carrying out the Ministry of Defense’s satellite constellation project, it has entered into a contract with Tri-Sat Constellation Co., Ltd. and Mitsui Bussan Aerospace Co., Ltd. for acquisition of optical imagery data. Tri-Sat Constellation Co., Ltd. is a special purpose company (SPC) established by Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, and Mitsui & Co., Ltd.

The Ministry of Defense’s satellite constellation project was awarded to a consortium comprising Mitsubishi Electric Corporation, SKY Perfect JSAT Corporation, Mitsui & Co., Ltd., Synspective Inc., Institute for Q-shu Pioneers of Space, Inc., Mitsui Bussan Aerospace Co., Ltd., and Axelspace. Tri-Sat Constellation Co., Ltd. signed the project with the Ministry of Defense for the project on February 19. Axelspace, as the sole provider of optical imagery among the partner companies, will contribute by satellite imagery acquisition to the project.

This project is a Private Finance Initiative (PFI) project aimed at building a satellite constellation operated by private-sector companies to ensure stable acquisition of imagery intelligence necessary for ensuring the effectiveness of stand-off defense capabilities*.

* Stand-off defense capabilities are the ability to effectively counter external attacks from a distant position outside the threat range.

“Under the recently concluded contract, Axelspace will participate as the sole optical imagery provider,” said Yuya Nakamura, President and CEO of Axelspace Corporation. “Based on the satellite development and operation technologies we have built to date, as well as our track record of stable image data provision, we aim to accurately address the needs of the national security field. At the same time, we will continue to actively expand the utilization of satellite data in the private sector and emerging markets, which are expected to see significant growth in the future.”

For the full press release, please visit: https://www.axelspace.com/news/satellite_constellation_project/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260220758297/en/

Permalink

https://www.aetoswire.com/en/news/2002202653464

Contacts

Media Contact

Axelspace Holdings Corporation

pr@axelspace.com

Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results

 LAS VEGAS -

Fourth Quarter and Full Year 2025 Financial Highlights Include:

Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior year

Adjusted Calculated Billings, full year 2025, up 4.2% from the prior year

Adjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year

 

(BUSINESS WIRE)--Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025.

“Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind down. We grew our core Rimini Support™ subscription billings and launched our next generation Agentic AI ERP solutions that can be easily and quickly deployed over the top of existing ERP Software without the cost or risk of unnecessary ERP Software upgrades, migrations or replatforming,” said Seth Ravin, president and CEO, Rimini Street. “ERP Software is peaking technically, and we will deliver new ERP capabilities and ERP Process execution faster, better and cheaper with more agility and speed to market leveraging Rimini Street’s Agentic AI ERP solutions. Meanwhile, we will keep existing ERP Software and releases delivering value for many years to come at significant savings.”

“Our fourth quarter results exceeded the guidance range we communicated at our Investor Day and demonstrate continued positive momentum entering 2026,” said Michael Perica, CFO, Rimini Street. “We invested in the development and launch of new AI-based solutions, streamlined global operations, achieved new RPO records in both the third and fourth quarters with increased year over year and sequential growth, increased our net cash year over year and ended fiscal year 2025 with a strong balance sheet and cash position. Capital allocation actions during the year included share repurchases and full repayment of the revolving line of credit.”

Select Fourth Quarter 2025 Financial Results

Revenue was $109.8 million for the fourth quarter of 2025, a decrease of 3.9% compared to $114.2 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, revenue decreased by 0.4%.

U.S. revenue was $47.5 million for the fourth quarter of 2025, a decrease of 10.6% compared to $53.1 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, U.S. revenue decreased by 4.3%.

International revenue was $62.3 million for the fourth quarter of 2025, an increase of 2.0% compared to $61.1 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, international revenue increased by 2.6%.

Subscription revenue was $104.9 million, which accounted for 95.6% of total revenue for the fourth quarter of 2025, compared to subscription revenue of $109.1 million, which accounted for 95.5% of total revenue for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, subscription revenue was $101.0 million, or 95.5% of total revenue, for the fourth quarter of 2025 compared to $101.4 million, or 95.5% of total revenue, for the same period last year.

Annualized Recurring Revenue was $411.4 million for the fourth quarter of 2025, a decrease of 0.8% compared to $414.8 million for the same period last year; excluding the support services for Oracle’s PeopleSoft software products, Adjusted Annualized Recurring Revenue was $395.8 million for the fourth quarter of 2025, an increase of 3.1% compared to $384.0 million for the same period last year.

Active Clients as of December 31, 2025 were 3,102, an increase of 0.7% compared to 3,081 Active Clients as of December 31, 2024.

Revenue Retention Rate was 88% and 88% for the trailing 12 months ended December 31, 2025 and 2024, respectively.

Calculated Billings was $171.3 million for the fourth quarter of 2025, a decrease of 0.4% compared to $172.1 million for the same period last year.

Adjusted Calculated Billings, which excludes Calculated Billings related to the support services for Oracle’s PeopleSoft software products, was $167.3 million for the fourth quarter of 2025, an increase of 0.7% compared to $166.2 million for the same period last year.

Remaining Performance Obligations (RPO) was a record $652.9 million as of December 31, 2025, an increase of 11.1% compared to $587.9 million as of December 31, 2024; excluding the support services for Oracle’s PeopleSoft software products, Adjusted RPO was $632.2 million as of December 31, 2025, an increase of 11.7% compared to $565.9 million as of December 31, 2024.

Gross margin was 60.4% for the fourth quarter of 2025 compared to 63.7% for the same period last year.

Operating income was $5.0 million for the fourth quarter of 2025 compared to an operating income of $14.9 million for the same period last year.

Non-GAAP Operating Income was $10.3 million for the fourth quarter of 2025 compared to $19.1 million for the same period last year.

Net income was $0.7 million for the fourth quarter of 2025 compared to $6.7 million for the same period last year.

Non-GAAP Net Income was $6.0 million for the fourth quarter of 2025 compared to $10.8 million for the same period last year.

Adjusted EBITDA for the fourth quarter of 2025 was $11.5 million compared to $20.0 million for the same period last year.

Both the basic and diluted earnings per share attributable to common stockholders were $0.01 for the fourth quarter of 2025, compared to a basic and diluted earnings per share of $0.07 for the same period last year.

Cash and cash equivalents were $120.0 million at December 31, 2025 compared to $88.8 million at December 31, 2024.

Repurchased approximately 1.0 million shares of Common Stock for approximately $3.8 million at an average price of $3.92 per share during the fourth quarter of 2025.

Select Full Year 2025 Financial Results

Revenue was $421.5 million for 2025, a decrease of 1.7% compared to $428.8 million for 2024; excluding the support services for Oracle’s PeopleSoft software products, revenue increased by 1.0%.

Calculated Billings was $427.9 million for 2025, an increase of 1.2% compared to $423.0 million for the same period last year.

Adjusted Calculated Billings, which excludes Calculated Billings related to the support services for Oracle’s PeopleSoft software products, was $414.2 million for 2025, an increase of 4.2% compared to $397.4 million for the same period last year.

Gross margin was 60.4% for 2025 compared to 60.9% for 2024.

Operating income was $59.9 million for 2025 compared to an operating loss of $32.1 million for 2024.

Non-GAAP Operating Income was $44.1 million for 2025 compared to $47.7 million for 2024.

Net income was $37.1 million for 2025 compared to a net loss of $36.3 million for 2024.

Non-GAAP Net Income was $21.3 million for 2025 compared to $43.6 million for 2024.

Adjusted EBITDA was $49.8 million for 2025 compared to $53.1 million for 2024.

Basic and diluted net earnings per share attributable to common stockholders were $0.40 and $0.39, respectively, for 2025, compared to a basic and diluted net loss per share of $(0.40) and $(0.40), respectively, for 2024.

Repurchased approximately 1.9 million shares of Common Stock for approximately $7.6 million at an average price of $4.07 per share during 2025.

Select Fourth Quarter 2025 Operating Results

Announced new and existing clients that expanded their agreements with Rimini Street, including the following:

Ypê, a leading Brazilian consumer goods company and a Rimini Street SAP S/4HANA support client, is accelerating its Agentic AI initiatives through the adoption of Rimini Street’s Agentic UX platform.

Tidewater, the world’s largest offshore service vessel operator, expanded its partnership with Rimini Street by adding Rimini Connect™ and Rimini Consult™ to address critical interoperability challenges.

Silicon Labs, a leading U.S.-based provider of semiconductor solutions, software, and IoT technologies, expanded its partnership with Rimini Street through a new five‑year agreement. The engagement includes support for its SAP ECC 6.0 environment and leverages Rimini Consult™ services to advance modernization initiatives including Agentic AI–driven ERP innovation solutions.

SP Electricity North West eliminated recurring SAP issues, cut maintenance costs by 50% and boosted service‑desk efficiency by 10% after implementing Rimini Street’s ERP support and single sign‑on optimization solution.

Unveiled groundbreaking “Agentic AI ERP” vision in a new white paper, declaring traditional ERP software obsolete and introducing a next‑generation, AI‑driven architecture that delivers faster, more agile, lower‑cost innovation—deployed over existing ERP systems with no required upgrades.

Launched 20 new Rimini Agentic UX™ Solutions, Powered by ServiceNow®, delivering rapid, AI‑driven ERP process automation that improves productivity, reduces costs and deploys in days or weeks—without requiring ERP upgrades, migrations or replatforming.

Announced that thousands of organizations now rely on the Rimini Smart Path™—a three‑step Support, Optimize, and Innovate methodology—to free budget, reduce operational burden, and accelerate AI‑driven innovation without costly ERP upgrades or migrations.

Received multiple industry honors recognizing its AI innovation, technical excellence and client‑first culture, including the Tech Ascension Award for AI‑Powered Enterprise (Agent) Solution of the Year, the Top Tech of the Year Award in Las Vegas honoring CEO Seth Ravin, the Silver Globee Award for Customer Service Team of the Year, and recognition for client Hitachi Vantara’s Gauri Kapur, winner of the 2025 Women Leading IT Award.

Announced a new global survey of nearly 4,300 C‑suite leaders, which revealed intensifying pressure to deliver AI‑driven innovation, stronger ROI and greater business resilience as executives navigate rising costs, increasing risk, persistent IT talent shortages, and frustration with vendor‑driven ERP roadmaps.

Announced a new global survey that finds Oracle Database customers are shifting strategies due to high costs, support challenges and growing demand for advanced AI/ML capabilities, with many turning to third‑party support to reduce fees, improve responsiveness, and unlock resources for innovation.

Announced global study of 455 SAP customers that finds strong shift toward multi‑vendor composable ERP, with organizations using third‑party support achieving above‑average performance 83% of the time versus 27% with traditional SAP‑led approaches.

Hosted an Investor Day on December 3, 2025 with videos and presentations posted and available for viewing on the Rimini Street Investor Relations website for one year.

Resolved more than 7,100 support cases and delivered over 10,800 tax, legal, and regulatory updates across 32 countries, achieving an average client satisfaction score above 4.9 out of 5.0 (where 5.0 is rated excellent).

Business Outlook

The Company is providing first quarter 2026 revenue guidance to be in the range of $101.5 million to $103.5 million and reiterating full year 2026 guidance as communicated at the Company’s Investor Day for revenue growth in the 4% to 6% range with Adjusted EBITDA margins in the 12.5% to 15.5% range.

Webcast and Conference Call Information

Rimini Street will host a conference call and webcast to discuss the fourth quarter and full year 2025 results and offer commentary on 2026 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on February 19, 2026. A live webcast of the event will be available on Rimini Street’s Investor Relations site at Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference call by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event.

Company’s Use of Non-GAAP Financial Measures

This press release contains certain “non-GAAP financial measures.” Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by U.S. generally accepted accounting principles, or GAAP. Non-GAAP financial measures should be considered in addition to, and not as a substitute for or superior to, financial measures determined in accordance with GAAP.

Reconciliations of the non-GAAP financial measures included in this press release and described below to their most directly comparable GAAP financial measures are provided in the financial tables included at the end of this press release. An explanation of these measures, why we believe they are meaningful and how they are calculated is also included under the heading “About Non-GAAP Financial Measures and Certain Key Metrics.”

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation.

To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for enterprise resource planning (ERP) software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; our wind down of support services for Oracle PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs, including those imposed by the United States government and the potential for retaliatory trade measures by affected countries; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States government and international governments and capture new contracts with governmental entities/agencies; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Annual Report on Form 10-K filed on February 19, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

RIMINI STREET, INC.

Unaudited Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

ASSETS

December 31,

2025

 

December 31, 2024

Current assets:

 

 

 

Cash and cash equivalents

$

119,974

 

 

$

88,792

 

Restricted cash, current

 

341

 

 

 

430

 

Accounts receivable, net of allowance of $1,443 and $653, respectively

 

136,866

 

 

 

130,784

 

Deferred contract costs, current

 

17,734

 

 

 

17,076

 

Prepaid expenses and other

 

25,447

 

 

 

19,194

 

Total current assets

 

300,362

 

 

 

256,276

 

Long-term assets:

 

 

 

Restricted cash, noncurrent

 

785

 

 

 

—

 

Property and equipment, net of accumulated depreciation and amortization of $23,822 and $21,305, respectively

 

10,239

 

 

 

9,891

 

Operating lease right-of-use assets

 

21,371

 

 

 

7,161

 

Deferred contract costs, noncurrent

 

24,436

 

 

 

22,084

 

Deposits and other

 

8,379

 

 

 

5,068

 

Deferred income taxes, net

 

57,540

 

 

 

68,583

 

Total assets

$

423,112

 

 

$

369,063

 

LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

Current liabilities:

 

 

 

Current maturities of long-term debt

$

4,031

 

 

$

3,093

 

Accounts payable

 

5,752

 

 

 

5,275

 

Accrued compensation, benefits and commissions

 

39,609

 

 

 

33,586

 

Other accrued liabilities

 

24,307

 

 

 

20,688

 

Operating lease liabilities, current

 

4,984

 

 

 

3,967

 

Deferred revenue, current

 

268,717

 

 

 

257,983

 

Total current liabilities

 

347,400

 

 

 

324,592

 

Long-term liabilities:

 

 

 

Long-term debt, net of current maturities

 

63,156

 

 

 

82,187

 

Deferred revenue, noncurrent

 

18,824

 

 

 

23,214

 

Operating lease liabilities, noncurrent

 

18,843

 

 

 

7,064

 

Other long-term liabilities

 

1,918

 

 

 

1,451

 

Total liabilities

 

450,141

 

 

 

438,508

 

Stockholders' deficit:

 

 

 

Preferred Stock, $0.0001 par value per share. Authorized 99,820 shares (excluding

180 shares of Series A Preferred Stock); no other series has been designated

 

—

 

 

 

—

 

Common Stock, $0.0001 par value. Authorized 1,000,000 shares; issued and outstanding 91,603 and 91,120 shares, respectively

 

9

 

 

 

9

 

Additional paid-in capital

 

181,075

 

 

 

177,533

 

Accumulated other comprehensive loss

 

(5,613

)

 

 

(7,389

)

Accumulated deficit

 

(201,384

)

 

 

(238,482

)

Treasury stock,, at cost, 137 and 137 shares, respectively

 

(1,116

)

 

 

(1,116

)

Total stockholders' deficit

 

(27,029

)

 

 

(69,445

)

Total liabilities and stockholders' deficit

$

423,112

 

 

$

369,063

 

RIMINI STREET, INC.

Unaudited Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

 

Three Months Ended

 

Year Ended

 

December 31,

 

December 31,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Revenue

$

109,790

 

 

$

114,213

 

 

$

421,536

 

 

$

428,753

 

Cost of revenue

 

43,514

 

 

 

41,501

 

 

 

166,935

 

 

 

167,731

 

Gross profit

 

66,276

 

 

 

72,712

 

 

 

254,601

 

 

 

261,022

 

Operating expenses:

 

 

 

 

 

 

 

Sales and marketing

 

41,355

 

 

 

37,437

 

 

 

151,569

 

 

 

149,736

 

General and administrative

 

17,380

 

 

 

18,624

 

 

 

69,997

 

 

 

73,084

 

Reorganization costs

 

2,555

 

 

 

1,098

 

 

 

4,491

 

 

 

5,737

 

Litigation costs and related recoveries:

 

 

 

 

 

 

 

Litigation settlement

 

—

 

 

 

—

 

 

 

(36,196

)

 

 

58,512

 

Professional fees and other costs of litigation

 

21

 

 

 

675

 

 

 

4,831

 

 

 

6,081

 

Litigation costs and related recoveries, net

 

21

 

 

 

675

 

 

 

(31,365

)

 

 

64,593

 

Total operating expenses

 

61,311

 

 

 

57,834

 

 

 

194,692

 

 

 

293,150

 

Operating income (loss)

 

4,965

 

 

 

14,878

 

 

 

59,909

 

 

 

(32,128

)

Non-operating income and (expenses):

 

 

 

 

 

 

 

Interest expense

 

(1,401

)

 

 

(1,904

)

 

 

(6,151

)

 

 

(6,305

)

Other income (expenses), net

 

187

 

 

 

(24

)

 

 

1,873

 

 

 

1,790

 

Income (loss) before income taxes

 

3,751

 

 

 

12,950

 

 

 

55,631

 

 

 

(36,643

)

Income tax benefit (expense)

 

(3,027

)

 

 

(6,291

)

 

 

(18,533

)

 

 

371

 

Net income (loss)

$

724

 

 

$

6,659

 

 

$

37,098

 

 

$

(36,272

)

 

 

 

 

 

 

 

 

Net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

Basic

$

0.01

 

 

$

0.07

 

 

$

0.40

 

 

$

(0.40

)

Diluted

$

0.01

 

 

$

0.07

 

 

$

0.39

 

 

$

(0.40

)

Weighted average number of shares of Common Stock outstanding:

 

 

 

 

 

 

 

Basic

 

91,395

 

 

 

90,979

 

 

 

91,736

 

 

 

90,503

 

Diluted

 

94,641

 

 

 

91,493

 

 

 

94,490

 

 

 

90,503

 

RIMINI STREET, INC.

GAAP to Non-GAAP Reconciliations

(In thousands)

 

Three Months Ended

 

Year Ended

 

December 31,

 

December 31,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Non-GAAP operating income reconciliation:

 

 

 

 

 

 

 

Operating income (loss)

$

4,965

 

 

$

14,878

 

 

$

59,909

 

 

$

(32,128

)

Non-GAAP adjustments:

 

 

 

 

 

 

 

Litigation costs and related recoveries, net

 

21

 

 

 

675

 

 

 

(31,365

)

 

 

64,593

 

Stock-based compensation expense

 

2,711

 

 

 

2,408

 

 

 

11,071

 

 

 

9,545

 

Reorganization costs

 

2,555

 

 

 

1,098

 

 

 

4,491

 

 

 

5,737

 

Non-GAAP operating income

$

10,252

 

 

$

19,059

 

 

$

44,106

 

 

$

47,747

 

Non-GAAP net income reconciliation:

 

 

 

 

 

 

 

Net income (loss)

$

724

 

 

$

6,659

 

 

$

37,098

 

 

$

(36,272

)

Non-GAAP adjustments:

 

 

 

 

 

 

 

Litigation costs and related recoveries, net

 

21

 

 

 

675

 

 

 

(31,365

)

 

 

64,593

 

Stock-based compensation expense

 

2,711

 

 

 

2,408

 

 

 

11,071

 

 

 

9,545

 

Reorganization costs

 

2,555

 

 

 

1,098

 

 

 

4,491

 

 

 

5,737

 

Non-GAAP net income

$

6,011

 

 

$

10,840

 

 

$

21,295

 

 

$

43,603

 

Non-GAAP Adjusted EBITDA reconciliation:

 

 

 

 

 

 

 

Net income (loss)

$

724

 

 

$

6,659

 

 

$

37,098

 

 

$

(36,272

)

Non-GAAP adjustments:

 

 

 

 

 

 

 

Interest expense

 

1,401

 

 

 

1,904

 

 

 

6,151

 

 

 

6,305

 

Income taxes

 

3,027

 

 

 

6,291

 

 

 

18,533

 

 

 

(371

)

Depreciation and amortization expense

 

1,022

 

 

 

947

 

 

 

3,861

 

 

 

3,596

 

EBITDA

 

6,174

 

 

 

15,801

 

 

 

65,643

 

 

 

(26,742

)

Non-GAAP adjustments:

 

 

 

 

 

 

 

Litigation costs and related recoveries, net

 

21

 

 

 

675

 

 

 

(31,365

)

 

 

64,593

 

Stock-based compensation expense

 

2,711

 

 

 

2,408

 

 

 

11,071

 

 

 

9,545

 

Reorganization costs

 

2,555

 

 

 

1,098

 

 

 

4,491

 

 

 

5,737

 

Adjusted EBITDA

$

11,461

 

 

$

19,982

 

 

$

49,840

 

 

$

53,133

 

Calculated Billings:

 

 

 

 

 

 

 

Revenue

$

109,790

 

 

$

114,213

 

 

$

421,536

 

 

$

428,753

 

Deferred revenue, current and noncurrent, end of the period

 

287,541

 

 

 

281,197

 

 

 

287,541

 

 

 

281,197

 

Deferred revenue, current and noncurrent, beginning of the period

 

225,999

 

 

 

223,314

 

 

 

281,197

 

 

 

286,974

 

Change in deferred revenue

 

61,542

 

 

 

57,883

 

 

 

6,344

 

 

 

(5,777

)

Calculated billings

 

171,332

 

 

 

172,096

 

 

 

427,880

 

 

 

422,976

 

Less PeopleSoft calculated billings

 

(4,039

)

 

 

(5,918

)

 

 

(13,728

)

 

 

(25,619

)

Adjusted calculated billings

$

167,293

 

 

$

166,178

 

 

$

414,152

 

 

$

397,357

 

RIMINI STREET, INC.

GAAP to Non-GAAP Reconciliations

(In thousands)

 

 

Three Months Ended

 

 

December 31,

 

 

2025

 

2024

Annualized recurring revenue

 

$

411,435

 

$

414,764

Less annualized PeopleSoft recurring revenue

 

 

15,630

 

 

30,720

Adjusted annualized recurring revenue

 

$

395,805

 

$

384,044

 

 

 

 

 

 

 

December 31, 2025

 

December 31, 2024

Remaining performance obligations

 

$

652,947

 

$

587,941

Less PeopleSoft remaining performance obligations

 

 

20,700

 

 

22,089

Adjusted remaining performance obligations

 

$

632,247

 

$

565,852

About Non-GAAP Financial Measures and Certain Key Metrics

To provide investors and others with additional information regarding Rimini Street’s results, we have disclosed the following non-GAAP financial measures and certain key metrics. We have described below Active Clients, Annualized Recurring Revenue, Adjusted Annualized Recurring Revenue and Revenue Retention Rate, each of which is a key operational metric for our business. In addition, we have disclosed the following non-GAAP financial measures: non-GAAP operating income, non-GAAP net income, EBITDA, Adjusted EBITDA, Calculated Billings, Adjusted Calculated Billings, Remaining Performance Obligations and Adjusted Remaining Performance Obligations. Rimini Street has provided in the tables above a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. There were no tax effects associated with any of our non-GAAP adjustments. These non-GAAP financial measures are also described below.

The primary purpose of using non-GAAP measures is to provide supplemental information that management believes may prove useful to investors and to enable investors to evaluate our results in the same way management does. We also present the non-GAAP financial measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis, as well as comparing our results against the results of other companies, by excluding items that we do not believe are indicative of our core operating performance. Specifically, management uses these non-GAAP measures as measures of operating performance; to prepare our annual operating budget; to allocate resources to enhance the financial performance of our business; to evaluate the effectiveness of our business strategies; to provide consistency and comparability with past financial performance; to facilitate a comparison of our results with those of other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results; and in communications with our board of directors concerning our financial performance. Investors should be aware however, that not all companies define these non-GAAP measures consistently.

Active Client is a distinct entity that purchases our services to support a specific product, including a company, an educational or government institution, or a business unit of a company. For example, we count as two separate active clients when support for two different products is being provided to the same entity. We believe that our ability to expand our active clients is an indicator of the growth of our business, the success of our sales and marketing activities, and the value that our services bring to our clients.

Annualized Recurring Revenue is the amount of subscription revenue recognized during a fiscal quarter and multiplied by four. This gives us an indication of the revenue that can be earned in the following 12-month period from our existing client base, assuming no cancellations or price changes occur during that period. Subscription revenue excludes any non-recurring revenue, which has been insignificant to date.

Adjusted Annualized Recurring Revenue is annualized recurring revenue adjusted to exclude PeopleSoft subscription revenue recognized during a fiscal quarter and multiplied by four.

Revenue Retention Rate is the actual subscription revenue (dollar-based) recognized over a 12-month period from customers that were clients on the day prior to the start of such 12-month period, divided by our Annualized Recurring Revenue as of the day prior to the start of the 12-month period.

Non-GAAP Operating Income is operating income (loss) adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs. The exclusions are discussed in further detail below.

Non-GAAP Net Income is net income (loss) adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs. These exclusions are discussed in further detail below.

Specifically, management excludes the following items from its non-GAAP financial measures, as applicable, for the periods presented:

Litigation Costs and Related Recoveries, Net: Litigation costs and the associated litigation settlement, insurance and appeal recoveries relate to outside costs of litigation activities. These costs and recoveries reflect the litigation we are involved with, and do not relate to the day-to-day operations or our core business of serving our clients.

Stock-Based Compensation Expense: Our compensation strategy includes the use of stock-based compensation to attract and retain employees. This strategy is principally aimed at aligning employee interests with those of our stockholders and to achieve long-term employee retention. As a result, stock-based compensation expense varies for reasons that are generally unrelated to operational decisions in any particular period.

Reorganization Costs: The costs consist primarily of severance costs associated with the Company's reorganization plan.

EBITDA is net income (loss) adjusted to exclude: interest expense, income taxes, and depreciation and amortization expense.

Adjusted EBITDA is EBITDA adjusted to exclude: litigation costs and related recoveries, net, stock-based compensation expense and reorganization costs, as discussed above.

Calculated Billings represents the change in deferred revenue for the current period plus revenue for the current period.

Adjusted Calculated Billings is calculated billings adjusted to exclude the calculated billings associated with PeopleSoft services.

Remaining Performance Obligations represent all future non-cancellable revenue under contract that has not yet been recognized as revenue, and includes deferred revenue and unbilled amounts.

Adjusted Remaining Performance Obligations is the Company's remaining performance obligations adjusted to exclude the remaining performance obligations for PeopleSoft.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260219293814/en/

Permalink

https://aetoswire.com/en/news/2002202653440

Contacts

Investor Relations Contact

Dean Pohl

Rimini Street, Inc.

+1 925 523-7636

dpohl@riministreet.com

Media Relations Contact

Janet Ravin

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com